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Mo3e is a protease-sensitive membrane antigen (p75,50) selectively expressed by human 
monocytic cells (monocytes and U-937 cells) stimulated in vitro by exposure to a variety of 
activating factors, including phorbol diester compounds, bacterial lipopolysaccharide (LPS), 
and muramyl dipeptide (MDP) (R. F. Todd et al., J. Immunol. 135,3869,1985). Here we report 
that primary and multiply-passaged cultures of HUVEC also express the Mo3e determinant 
after stimulation by phorbol myristate acetate (PMA) and related inducers of protein kinase C. 
As measured in a radioimmunoassay of anti-Mo3e antibody binding to monolayer cultures 
of HUVEC, unstimulated cells bore little if any Mo3e. After culture for 4- 120 hr in medium 
containing PMA, 4fl-phorbol dibutyrate, 4&phorbol didecanoate, or mezerein (each at a con- 
centration of 8 1 nM), or 1 -oleoyl-2-acetoyl-sn-3glycerol(l mM), HUVEC were found to selec- 
tively express the Mo3e determinant. The magnitude of expression was dependent upon the 
concentration ofthe stimulus, maximal by 24 hr, and inhibited by cycloheximide. The combina- 
tion of PMA and the calcium ionophore, ionomycin, had an additive or synergistic effect on 
HUVEC Mo3e expression. The biologically inactive phorbol compounds rl&phorbol and 4~ 
phorbol didecanoate failed to stimulate Mo3e expression. Also inactive as inducers of HUVEC 
Mo3e expression were crude lymphokine and monokine supematants, recombinant human 
lymphokines (interferon-y and interleukin-2), recombinant human monokines (interleukin-1 
and tumor necrosis factor), bacterial cell wall products including LPS and MDP, pharmacologic 
agents that increase intracellular cyclic adenosine monophosphate (prostaglandin Er, cholera 
toxin, theophylline, isoproterenol and isobutylmethylxanthine), lectins (Con A and PHA), and 
heparin. These results indicate that Mo3e is an inducible plasma membrane antigen of not only 
mononuclear phagocytes but also cultured HUVEC. o 1988 Academic her, IX. 
INTRODUCTION 
Cells of the mononuclear phagocyte system and endothelial cells display a number 
of similar physiological characteristics that include the capacity to ingest soluble and 
particulate matter (pinocytosis and phagocytosis, respectively) ( 1,2), to present anti- 
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genie material to T lymphocytes in association with plasma membrane Ia (class II) 
histocompatability determinants (3-6), and to synthesize and secrete certain soluble 
inflammatory mediators such as interleukin-1 (IL-l)” (7-9). The performance of 
these and other functional activities by mononuclear phagocytes and endothelial cells 
is up-regulated by exposure to a variety of inflammatory activating factors in vitro or 
in vivo (1, 5, 8, 9). The physiologic “activation” of macrophages and endothelial 
cells is often manifest by changes in morphology, metabolic activity, and plasma 
membrane composition. For example, exposure of human monocytes or human um- 
bilical vein endothelial cells (HUVEC) to interferon-y (IFN-y) in vitro stimulates the 
surface expression of Ia determinants ( lo- 14). Other changes in plasma membrane 
phenotype that occur as a consequence of activation include the enhanced surface 
expression of Fc receptors by interferon-stimulated human monocytes ( 15, 16) or by 
endothelial cells after cytomegalovirus (CMV) infection (17) ICAM- 1 (a molecule 
promoting cellular adhesion) by U-937 monoblasts stimulated with phorbol myris- 
tate acetate (PMA) (18) and by HUVEC exposed to IL- 1, IFN-r or tumor necrosis 
factor (TNF) ( 18, 19), and membrane-bound tissue factor (procoagulant activity) by 
human monocytes (20, 2 1) and HUVEC cultured in medium containing TNF (22, 
23), IL-l (24-27), or bacterial lipopolysaccharide (LPS) (24,25,27). 
The application of hybridoma-generated monoclonal antibody technology has led 
to the identification of additional activation associated plasma membrane determi- 
nants expressed by mononuclear phagocytes and/or endothelial cells. In the mononu- 
clear phagocyte system these include the acquired expression of the ACM. 1 (28), Asi- 
alo GM1 (29), 7/4 (30), MAA- (3 I), and MA158.2 (32, 33) antigenic determinants 
by murine macrophages activated in vivo (by BCG or Cornyebacterium parvum inoc- 
ulation) or in vitro (by lymphokines), and the expression of the Al-3 (34, 35) and 
Mo3e (36) antigens by human mononuclear phagocytes exposed to soluble-activating 
factors (LPS, PMA, IFN-7) in vitro. Likewise, Pober and his colleagues have demon- 
strated the expression of H4/ 18 by HUVEC activated in vitro by exposure to IL- 1, 
TNF, and LPS (37,38). 
With the goal of further characterizing the plasma membrane consequences of hu- 
man mononuclear phagocyte activation, we previously generated a murine mono- 
clonal antibody specific for an antigen, Mo3e (p75,50), expressed by human mono- 
cytes stimulated in vitro by exposure to soluble-activating factors including LPS, 
PMA, and MDP (36). In this report, we have demonstrated that surface Mo3e expres- 
sion is also selectively acquired by HUVEC cultured in medium containing PMA 
and certain other compounds known to stimulate the activation of protein kinase C. 
’ Abbreviations used: BSA, bovine serum albumin; CMV, cytomegalovirus; Con A, concanavalin A; 
cpm, counts per minute; DPBS, Dulbecco’s phosphate-buffered saline; ECGS, endothelial cell growth sup- 
plement; HUVEC, human umbilical vein endothelial cells; IL- 1, interleukin- 1; IFN-7, interferon-y; LPS, 
Escherichia coli lipopolysaccharide; LPS-MCM, lipopolysaccharide-stimulated monocyte-conditioned 
medium; MDP, muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoghttamine); MEZ, mezerein; NGS, 
normal goat serum; NP-40, Nonidet P-40 detergent; OAG, L-cr-1-oleoyl-2-acetoyl-sn-3-glycerol; PBMC, 
peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PHA, phytohemagglutinin; PHA- 
LCM, phytohemagglutinin-stimulated lymphocyte-conditioned medium; 4BPDB, 4fi-phorbol 12,13-dibu- 
tyrate; 4aPDD, 4cu-phorbol 12,13-didecanoate; 4@PDD, 4@-phorbol 12,13didecanoate; PMA, phorbol 
my&ate acetate (4&phorbol 12-myristate- 13-acetate); RIA, radioimmunoassay; TNF, tumor necrosis 
factor a; 1640-AS, RPM1 1640 medium supplemented with 10% autologous serum; MIF, migration inhibi- 
tory factor. 
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MATERIALS AND METHODS 
Media and reagents. The following media and tissue culture additives were pur- 
chased from GIBCO Laboratories (Grand Island, NY): Medium 199 with 25 mM 
Hepes buffer, Hanks’ salts and L-glutamine (380-2350); 200 mM L-glutamine (320- 
5030); penicillin-streptomycin solution (600-570); 1-X trypsin-EDTA (6 10-5300); 
RPM1 1640 (320- 1875). The following reagents were purchased from Sigma Chemi- 
cal Co. (St. Louis, MO): 4fi-phorbol (P8893); 4/3-phorbol 12,13-dibutyrate (4PPDB, 
P 1269); 4@-phorbol 12,13-didecanoate (4PPDD, P90 18); 4cy-phorbol 12,13-dideca- 
noate (4aPDD, P80 14); 4&phorbol 12-myristate 13-acetate (PMA, P8 139); dimethyl 
sulfoxide (DMSO, D5879); Escherichia coli LPS (L2755); phytohemagglutinin 
(PHA, L8504); cholera toxin (C30 12); 3-isobutyl- I-methylxanthine (IBMX; 15879); 
concanavalin A (Con A, C2010); cycloheximide (C6255); theophylline (T1633); iso- 
proterenol(I5627); bovine serum albumin (BSA, A4503); diaminobenzidine (DAB, 
D800 1); and Histopaque ( 1077- 1). Mezerein (MEZ, M4600) was purchased from LC 
Services Corp. (Woburn, MA). L-cu- 1 -Oleoyl-2-acetoyl-sn-3 glycerol (OAG, 800 100) 
was purchased from Avanti Polar Lipids, Inc. (Birmingham, AL). Ionomycin from 
Streptomycin conglobatus (407952) was purchased from Calbiochem (San Diego, 
CA). Ultrapure IL- 1 (GUPI- 1) was purchased from Genzyme (Boston, MA). Porcine 
heparin (1000 u/ml, 2440-4 1) was purchased from Elkins-Sinn, Inc. (Cherry Hill, 
NJ). Recombinant interleukin-2 (IL-2, CPL IA-0 12) and recombinant TNF-a (Lot 
NP 102) were gifts of the Cetus Corp. (Emeryville, CA). Recombinant human IIN- 
(Ro 23-4400) was a gift of Dr. Sidney Pestka, Roche Institute of Molecular Biology 
(Nutley, NJ). Hanks’ balanced salts solution without phenol red, calcium, or magne- 
sium (55-02577) was purchased from Hazleton Research Products, Inc. (Lenexa, 
KA). Endothelial cell growth supplement (ECGS) was purchased from Collaborative 
Research Products (Cambridge, MA). Lactated Ringer’s solution was purchased from 
Abbott (North Chicago, IL). Type I collagenase was purchased from Worthington 
Biochemical (Freehold, NJ). Amphotericin B was purchased from E. R. Squibb & 
Sons, (Princeton, NJ). NP-40 was purchased from Particle Data Laboratories, Ltd. 
(Elmhurst, IL). Phosphate-buffered formalin solution (lo%, SO-F-loo) was pur- 
chased from Fisher Scientific (Fairlawn, NJ). 
PMA, 4PPDB, 4PPDD, 4aPDD, 4&phorbol, MEZ, and OAG were initially di- 
luted in DMSO to make stock solutions of 1 mg/ml which were stored at -80°C. 
Ionomycin was kept as a 4 n04 solution in DMSO and stored at -80°C. 
Antibodies used. The generation and characterization of murine monoclonal anti- 
bodies anti-MO 1 (anti-CD1 lb, IgG2a, clone 44) (39), anti-MO1 (anti-CD1 lb, IgM, 
clone 17) (40), anti-MO2 (anti-CD14, IgG2b, clone 26) (4 l), anti-Mo3e (IgM, clone 
109) (36), anti-13 (anti-Ia, IgG2a, clone 9-49) (42), and anti&M (anti-HLA-A, B, C, 
IgG2b, clone 88) (43) have previously been described. The anti-&M was a generous 
gift of Dr. Lee Nadler of the Dana-Farber Cancer Institute (Boston, MA). Mono- 
clonal antibodies were diluted 1: 100 in Dulbecco’s phosphate-buffered saline (DPBS) 
with 1% BSA and 0.1% glucose (radioimmunoassay buffer (RIA-buffer)). Polyclonal 
‘251-labeled sheep F(ab’)2 anti-mouse immunoglobulin fragments (12?-SAM Ig) were 
purchased from DuPont, NEN Products (NEX- 162, Boston, MA) and used after di- 
lution in RIA-buffer to a final stock concentration of 2.5 X lo6 cpm/ml. 
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Endothelial cell cultures. HUVEC were harvested from normal term delivery hu- 
man umbilical cords by the method of Gimbrone et al. (44) and were serially propo- 
gated according to the protocol of Maciag et al. (45) as modified by Weiss and Regiani 
(46) in which endothelial cells were cultured in 20% pooled human serum. Except 
where indicated, HUVEC were propogated in Costar (Cambridge, MA) 24-well plates 
which had been precoated with a 0.2% gelatin solution. For the majority of experi- 
ments, primary and first-passage cultures were employed. In selected experiments, 
multiply-passaged cells were used (up to the sixth passage). At the time of passage, 
HUVEC monolayers were disrupted into single cell suspensions using trypsin-EDTA 
and then seeded onto fresh gelatin-coated plates. Cultures were fed three times weekly 
(complete medium change) with growth medium consisting of M 199 containing 20% 
pooled human serum, 100 u/ml penicillin, 100 u/ml streptomycin, 2.5 pg/ml ampho- 
tericin B, and 150 pg/ml ECGS. 
When confluent (4-6 days after seeding), 2.0-cm2 HUVEC monolayer cultures 
containing 0.5 ml of growth medium were stimulated by the addition of various solu- 
ble factors in 5- to loo-p1 volumes. For additives initially dissolved in DMSO, etha- 
nol, or methanol, the final solvent concentration did not exceed 0.5, 0.2, or 0.3%, 
respectively. In most experiments, HUVEC were subsequently cultured for an addi- 
tional 24 hr at 37°C in a humidified atmosphere of 5% COZ in air prior to RIA. In 
other experiments, HUVEC were cultured for varying lengths of time up to 120 hr. 
In selected experiments, HUVEC were seeded in gelatin-coated 35-mm culture 
dishes (Falcon Plastic Division of Becton-Dickinson Laboratories, Lincoln Park, 
NJ), and when confluent, cultured in the presence of stimulating factors as indi- 
cated above. 
Monocyte-conditioned medium. Peripheral blood mononuclear cells (PBMC) were 
isolated by Histopaque- 1077 density gradient centrifugation (47) of heparin-antico- 
agulated blood (4 u/ml) from healthy volunteer donors. Monocyte-rich adherent cells 
were obtained by incubating PBMC in 1640-AS (RPM1 1640 medium supplemented 
with 10% autologous serum) on loo-mm plastic culture dishes (Falcon Plastics, Ox- 
nard, CA) pretreated with autologous serum (48). After 60 min at 37°C nonadherent 
PBMC were aspirated off, and the plates were washed with five changes of 37°C HBSS 
(5 ml each wash). After washing, the monocyte cultures were fed with 5 ml of 1640- 
AS and cultured with 50 rig/ml LPS for 72 hr at 37°C in a humidified atmosphere of 
5% CO2 in air. The supernatant medium was then harvested by aspiration, filtered 
(0.22 pm), and stored at -80°C until use. 
Radioimmunoassay. In experiments designed to measure monoclonal antibody 
binding to 2.0-cm2 monolayer cultures of HUVEC, an indirect RIA was employed 
(all steps carried out at 4°C): The medium was removed sequentially from each well 
and 200 ~1 of a 1: 100 (saturating) dilution of the primary mouse monoclonal anti- 
body was added to each well and allowed to incubate for 30 min. For each experimen- 
tal antibody an isotype-identical negative control monoclonal antibody was run in 
parallel as a measure of nonspecific antibody binding. The primary antibody was 
then removed and each well was sequentially rinsed twice with 300 ~1 of RIA buffer 
prior to the addition of 200 ~1 of 12?-SAM Ig containing 5 X 1 O5 cpm. After a second 
30-min incubation, “‘I-SAM Ig was removed and each well was rinsed three times 
with 300 ~1 RIA-buffer solution. After the last wash the HUVEC cultures were solubi- 
lized by the addition of 400 ~1 DPBS containing 1% Nonidet P-40 (NP-40) and al- 
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lowed to incubate for 1 hr at room temperature. The cell lysates were then transferred 
to 8 X 75mm plastic tubes for counting in a TM-Analytic Gamma Trac 119 1 gamma 
scintillation counter (Elk Grove Village, IL). Specific 1251-SAM Ig binding was calcu- 
lated by subtracting the mean counts per minute (cpm) of triplicate cultures exposed 
to the negative control monoclonal antibody (generally IgM anti-MO 1) from that of 
triplicate cultures exposed to the experimental antibody (generally IgM anti-Mo3e). 
In selected experiments, HUVEC monolayers were fixed prior to RIA according to 
the following protocol: medium was removed and the monolayers were incubated in 
300 ~1 of PBS containing 10% formaldehyde for 10 min at 4°C. The monolayers were 
washed three times by the addition of 300 ~1 PBS and then incubated in 300 ~1 of a 
1: 1 solution of methanol:3% H202 in water for 10 min at 4°C. After three additional 
washes in PBS, the cells were subjected to RIA as above. 
Zmmunoperoxiduse assay. Immunocytochemical localization of antibody binding 
was carried out by a modification of the immunoperoxidase avidin-biotin complex 
technique (ABC method) described by Hsu et al. (49) using a Vectastain ABC kit 
(mouse IgM No. PK-40 10) purchased from Vector Labs (Burlington, CA). All steps 
were carried out at room temperature. Confluent monolayers of HUVEC grown on 
35-mm culture dishes were incubated in growth medium containing 50 rig/ml PMA 
or control medium for 24 hr prior to fixation as detailed in the preceding paragraph. 
The plates were washed three times with 2 ml of PBS and then incubated for 10 min 
in 2 ml of PBS containing 6% normal goat serum (NGS) and 4% BSA. The mono- 
layers were then exposed to 750 ~1 of the primary monoclonal antibodies (diluted 1: 
100 in PBS containing 1% NGS and 4% BSA) for 30 min, washed three times in PBS, 
and then exposed to 750 ~1 of the biotinylated goat anti-mouse IgM antibody (diluted 
1:200 in PBS containing 1% NGS and 4% BSA) for 30 min. After an additional three 
washes in PBS, 750 ~1 of ABC reagent was then added to each plate. The plates were 
again incubated for 30 min, washed twice in PBS, and then exposed to 0.04% diami- 
nobenzidine in PBS for 10 min. After two distilled HZ0 rinses, the plates were coun- 
terstained with hematoxylin and examined directly using an American Optical One- 
Twenty microscope. 
RESULTS 
As shown in Table 1, exposure of primary cultures of HUVEC to PMA (50 rig/ml 
for 24 hr at 37°C) induced the expression of Mo3e as detected in a RIA measuring 
the binding of anti-Mo3e monoclonal antibody to monolayers of PMA-stimulated 
and unstimulated HUVEC. Surface Mo3e expression by unstimulated HUVEC (af- 
ter subtraction of background antibody binding) was negative. To exclude the possi- 
bility that this increase in surface Mo3e was a manifestation of a generalized up- 
modulation of HUVEC plasma membrane components, we examined the binding 
of other monoclonal reagents specific for class I and II histocompatibility antigens 
&M and Ia, respectively), as well as selected isotype identical control reagents (anti- 
MO 1 and anti-Mo2) that identify myelomonocytic antigens not expressed by endo- 
thelial cells (50-52). It can be seen that culture of HUVEC in media containing PMA 
did not affect the surface expression of class I or II histocompatibility antigens. More- 
over, the increase in anti-Mo3e antibody binding to PMA-treated cells was not a 
consequence of an increase in the level of nonspecific antibody binding (as would be 
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TABLE 1 
Selective Surface Expression of Mo3e Antigen by PMA-stimulated HUVEC Monolayers” 
Monoclonal 
antibody (isotype) 








Anti-MO 1 (IgG2a) 
Anti-MO2 (IgG2b) 
RIA Buffer 
4,372 + 406 (3,285)’ 1,179k 118(134) 
14,162 k 443 (12,938) 14,133 k 532(12,696) 
1,919 f 392 (1,013) 1,912 f 155 (913) 
1,087 f 207 1,045 k 78 
906 f 133 999k 87 
1,224 f 96 1,437 f 43 
515+ 6 538 + 46 
a HUVEC monolayers (2.0 cm*, primary cultures) were cultured in medium containing either PMA (50 
@ml) or an equivalent amount of DMSO diluent (0. l%, unstimulated) for 24 hr at 37°C prior to RIA as 
described under Materials and Methods. 
b Mean cpm (‘2SI-SAM-Ig bound) + SD of triplicate determinations. 
‘Numbers in parentheses indicate specific ‘*‘I-SAM Ig binding: mean ‘251-SAM Ig bound to monolayers 
exposed to experimental antibodies minus mean ‘*%SAM Ig bound to monolayers exposed to isotype- 
identical control antibodies. 
detected by an increase in the binding of anti-MO1 and anti-MO2 negative control 
antibodies). In addition, there was no significant difference in the number of viable 
endothelial cells per monolayer in PMA-stimulated and unstimulated HUVEC at the 
time of the assay (data not shown), excluding the possibility that such a numerical 
difference could account for the results observed. On the basis of these results (repro- 
ducible in over 80 experiments), we conclude that unstimulated HUVEC express 
negligible quantities of surface Mo3e but that exposure to PMA induces the selective 
acquisition of surface Mo3e expression not only by primary cultures of HUVEC but 
also by multiply passaged cells (up to six passages; data not shown). 
By surface immunofluoresence analysis of unfixed PMA-stimulated HUVEC and 
by immunoperoxidase staining of formalin-fixed cells (data not shown), a diffuse pat- 
tern of Mo3e expression was observed, indicating that Mo3e expression by HUVEC 
is a feature shared by the vast majority of stimulated HUVEC. 
As seen in Figs. 1 and 2, the magnitude of surface Mo3e expression by PMA-stimu- 
lated HUVEC was directly related to the concentration of PMA and to the duration 
of stimulation. Peak Mo3e expression was observed at PMA concentrations exceed- 
ing 25 rig/ml (range 3-200 rig/ml) and after 14 hr of culture in media containing 
PMA (range 4- 120 hr). 
Since PMA is a stimulus of surface Mo3e expression by HUVEC, we then evalu- 
ated the stimulatory capacity of other related compounds that are known to activate 
protein kinase C in mammalian cells (reviewed in (53, 54)). As shown in Fig. 3, two 
other biologically active phorbol compounds, 4PPDD and 4/3PDB, stimulated the 
expression of surface Mo3e as did the related diterpene compound MEZ (55). In 
contrast, the biologically inert cr stereoisomer of 4PPDD and the parent alcohol 48- 
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FIG. 1. Surface expression of Mo3e antigen as a function of PMA concentration. Triplicate 2.0-cm* 
(first passage) HUVEC monolayers were cultured for 24 hr at 37°C in medium containing the indicated 
concentrations of PMA, or medium alone (control). The height of the bars represents specific surface 
expression of Mo3e as measured by specific ‘2SI-SAM-Ig binding detected by RIA as described under Mate- 
rials and Methods (mean cpm ? SD). The subtracted nonspecific (anti-Mol) binding was 1436, 1792, 
1868, 1596, 150 1, 19 11, 19 18, and 1666 (mean cpm, left to right). In control experiments (not shown), 
specific ‘251-SAM-Ig binding by cultures receiving DMSO diluent was indistinguishable from that of cul- 
tures to which no DMSO was added. The results of this experiment are representative of those seen in five 
similar experiments. 
I I 
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FIG. 2. Surface expression of Mo3e antigen as a function of the duration of PMA exposure. HUVEC 
(primary culture) monolayers (2 cm2) were cultured for 48 hr at 37°C; PMA (to make a final concentration 
of 50 r&ml) was added sequentially such that triplicate cultures were exposed to PMA for the indicated 
durations. In the “0-hr” duration cultures, PMA was added just prior to the RIA; “control” cultures re- 
ceived no PMA. As in Fig. 1, the height of the bars represents the mean specific ‘251-SAM-Ig binding + SD. 
The subtracted nonspecific (anti-Mol) binding was 1455, 1746, 1713, 1596,2459, and 2225 (mean cpm, 
left to right). As in Fig. 1, the addition of DMSO diluent alone had no effect on surface Mo3e expression. 
The results of this experiment are representative of those seen in three similar experiments. 
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FIG. 3. Surface expression of Mo3e antigen stimulated by other phorbol compounds, mezerein, and 
OAG. Triplicate 2.0-cm* HUVEC (first passage) monolayers were cultured for 24 hr at 37°C in the presence 
of the compounds listed. PMA, 4@PDD, 4@PDB, 4aPDD, 4&phorbol, and mezerein were all added such 
that the final concentration of each was 8 1 mt4 (equivalent to 50 rig/ml PMA, an appropriate control for 
the highest concentration of DMSO diluent to which the cells were exposed, 0.11% was included, as 
shown). As previously described (58), the OAG was added in 11 hourly doses to give a final concentration 
of 1 mM(OAG being rapidly degraded (56,57)). Parallel control cultures received DMSO to a final concen- 
tration of 0.5%. Other control cultures received no additives. The height of the bars represents the mean 
specific “‘1-SAM-Ig binding f the SD. Subtracted nonspecific (anti-Mol) binding was 1636, 1655, 1905, 
18 18, 1403, 172 1, 165 1, 1838, 1350, and 1672 (mean cpm, left to right). The results of this experiment are 
representative of those seen in three similar experiments. 
phorbol were inactive in stimulating Mo3e expression, These observations suggested 
a relationship between the capacity of these agents to stimulate the expression of 
Mo3e and their reported activity in stimulating protein kinase C activation (53, 54). 
This notion was further supported by the stimulatory effect of the cell-permeable 
diacylglycerol compound OAG which can mimic the effect of endogenous 1,2-diacyl- 
glycerol in stimulating protein kinase C activity (56,57) (Fig. 3). 
Because of reports demonstrating the synergistic effect of calcium ionophores and 
PMA in generating effector responses in other cellular systems (58-63), we then eval- 
uated the combined stimulatory capacity of ionomycin and PMA to induce surface 
Mo3e expression by HUVEC. In Fig. 4, it can be seen that ionomycin alone at a 
concentration of 1 PM had a modest stimulatory effect that was additive to that of 
PMA at the submaximally stimulatory concentrations of 5- 10 rig/ml. In several ex- 
periments as represented by the data in Fig. 4, ionomycin had a synergistic effect with 
PMA at the maximally stimulatory concentrations of 25-50 rig/ml. An increase in 
intracellular calcium induced by ionomycin may therefore promote surface Mo3e 
expression stimulated by PMA (5 3). 
To determine if protein synthesis is required for the surface expression of Mo3e on 
HUVEC stimulated by PMA, we examined the effect of cycloheximide when added 
to HUVEC cultures at the start of their incubation with PMA. As shown in Fig. 5, 
cycloheximide at a concentration of 1 pg/ml inhibited the surface expression of Mo3e 
by approximately 80%. This concentration of cycloheximide was noncytotoxic (as 
determined by trypan blue exclusion) and did not cause the detachment of PMA- 
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FIG. 4. PMA and ionomycin have additive or synergistic effects on surface Mo3e expression. Triplicate 
2.0-cm* HUVEC (primary culture) monolayers were cultured for 24 hr at 37°C in medium containing the 
indicated concentrations of PMA, either in the presence or in the absence of 1 ti ionomycin. The height 
of the bars represents the mean specific ?SAM-Ig binding f the SD. Subtracted nonspecific (anti-Mol) 
binding was 1118, 1102, 1131, 1400, 1145, 1543, 1095, and 1567 (mean cpm, left to right). The addition 
of DMSO diluent alone had no effect on surface Mo3e expression. The results of this experiment are 
representative of those seen in seven similar experiments. 
stimulated cells from the monolayer substrate (as did concentrations exceeding 2 pg/ 
ml). These data suggest a requirement for protein synthesis during induction of sur- 
face Mo3e expression stimulated by PMA. 
Immunoperoxidase staining of formalin/methanol-fixed HUVEC for the expres- 
sion of Mo3e demonstrated specific antibody binding to unstimulated HUVEC as 
well as to monolayers stimulated by PMA (data not shown). This suggested the possi- 
bility that while unstimulated HUVEC express little, if any, surface Mo3e (as deter- 
mined by RIA of viable unfixed cells), they may contain a sequestered pool of cy- 
FIG. 5. Inhibition of surface Mo3e expression by cycloheximide. Triplicate 2.0-cm2 HUVEC (first-pas- 
sage) monolayers were cultured for 24 hr at 37°C in medium containing 50 @ml PMA and the indicated 
concentrations of cycloheximide. Control monolayers were cultured in the absence of both PMA and 
cycloheximide. The height of the bars represents the mean specific “‘1-SAM-Ig binding + the SD. Sub- 
tracted nonspecific (anti-Mol) binding was 763,742,8 16,1013, and 1072 (mean cpm, left to right). At the 
concentrations of cycloheximide tested, HUVEC monolayers remained confluent and excluded trypan 
blue. The results of this experiment are representative of those seen in four similar experiments. 
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TABLE 2 
Detection of Mo3e Antigen in Formalin-Fixed, Unstimulated HUVEC” 
Specific ‘2SI-SAM Ig binding (mean -t SD) 
Expt. No. 
Unfixed Formalin-fixed 
PMA-stimulated Unstimulated PMA-stimulated Unstimulated 
1 3540 f 256’ 447+ 50 2591 f 292 2136 f 171 
(1026) (1421) (6586) (673 1) 
2 2130& 78 356 f I14 2172 + 168 I394 f 402 
(1172) (1527) (6393) (6440) 
3 3049 f 128 417 + 132 2713_+510 1431+328 
(901) (987) (4876) (5042) 
’ HUVEC monolayers (2.0 cm2, primary cultures in Experiments 1 and 2; fifth-passage cultures in Exper- 
iment 3) were cultured in medium containing either PMA (50 rig/ml) or no additive (unstimulated) for 24 
hr at 37’C. Parallel triplicate monolayers were then either formalin-fixed (see Materials and Methods) or 
left unfixed prior to RIA for the expression of Mo3e (as measured by specific ‘ZSI-SAM Ig binding). 
b Specific “‘I-SAM Ig binding (mean cpm f SD of triplicate determinations). 
’ ‘251-SAM Ig binding (mean of triplicate determinations) to monolayers exposed to isotype-identical 
negative control reagent (anti-Mol), i.e., background binding. In Experiments 1 and 2, ‘251-SAM Ig binding 
to anti-Mo2treated monolayers (as an additional IgM-negative control) was nearly identical to that shown 
for anti-MO 1. 
toplasmic antigen. This conclusion was supported by the results of quantitative RIA 
in which significant levels of specific anti-Mo3e binding to fixed, unstimulated HU- 
VEC was detected (Table 2). The greater magnitude of specific anti-Mo3e binding 
to fixed PMA-stimulated cells over that bound to fixed unstimulated HUVEC may 
indicate the synthesis of new antigen in addition to that found in pre-existing cy- 
toplasmic pools. 
As indicated in Table 3, we evaluated the stimulatory activity of other soluble fac- 
tors in addition to PMA that have been reported to either up-regulate endothelial cell 
and/or macrophage functional activity or to increase the surface expression of plasma 
membrane receptors and antigenic determinants: lymphokines and monokines 
(PHA-stimulated lymphocyte-conditioned media (PHA-LCM) (64), recombinant 
IFN-7 (5, 8- 14, 18) IL-2 (65), LPS-stimulated monocyte-conditioned media (LPS- 
MCM) (7), IL-1 (18, 19,24-27), TNF (19,22,23)), bacterial cell wall products (LPS 
and MDP (24, 25, 27, 36)), lectins (PHA (66) and Con-A (7)), drugs that raise the 
intracellular concentration of cyclic adenosine monophosphate (cyclic AMP) (chol- 
era toxin, isoproterenol, theophylline, IBMX, and PGE-2 (67-70)), and heparin (en- 
dothelial cell growth stimulatory activity (7 1)). Whereas crude lymphokine and mo- 
nokine supernatants, bacterial cell wall products, certain recombinant lymphokines, 
and monokines stimulated morphologic changes characteristic of those seen in HU- 
VEC monolayers stimulated by PMA (Table 3) there was no reproducible parallel 
stimulation of surface Mo3e expression by these factors when tested over broad con- 
centration ranges and at exposures lasting from 4 to 72 hr. The only exception was a 
variable degree of low magnitude surface Mo3e expression stimulated by either PHA 
or PHA-LCM. 
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TABLE 3 
Factors That Fail to Stimulate the Surface Expression of Mo3e by HUVEC 
Concentration Duration’ Morphologic Experiments 
Stimulus range tested (hr) changesb WY 
PHA-LCMd 5-20% 4-12 ++ 4 
LPS-MCM l-10% 24-12 ++ 3 
IL- 1 0.5-20 u/ml 24-12 + 2 
TNF lo- 1,000 u/ml 4-120 +++ 5 
IFN-y lo-1,000 r/ml 4-120 ++t I 
IL-2 lo-10,000 u/ml 4-12 - 4 
E. coli LPS 0.0 l-3 1 &ml 4-12 t 5 
MDP O.l-IOlrM 4-12 ++ 4 
PHAd 0.5-250 rg/ml 24 tt 4 
Con A 0.05-50 j@ml 24 f 2 
Cholera toxin l-100 rig/ml 4-12 - I 
Isoproterenol 5-500& 4-24 - 3 
PGEZ O.I-10pM 4-24 - 4 
Theophylline 0.05-l.OmM 4-24 - 3 
IBMX 0.05-l.OmM 4-24 - 4 
Heparin 3.75-60 u/ml 24 - 2 
LI Duration of culture period during which HUVEC monolayers were exposed to stimuli. 
b Degree to which monolayer cells exhibited a “whorling” morphology: ranging from (-), no shape 
changes observed, to (tt+) majority of monolayer cells exhibiting marked shape changes similar to that 
stimulated by PMA. 
c Number of separate experiments performed. 
d Poorly reproducible, low-level expression of surface Mo3e induced. 
DISCUSSION 
Based upon previous studies involving human mononuclear phagocytes, Mo3e is 
a protease-sensitive antigen (~7550) that is selectively expressed by human mono- 
cytes and myelomonocytic cell lines after exposure in vitro to soluble activating fac- 
tors that include PMA and certain other biologically active phorbol compounds, bac- 
terial LPS, and MDP (72). As shown in this report, the surface expression of Mo3e is 
also a feature characteristic of HUVEC stimulated by PMA and related compounds. 
Control experiments demonstrated that the acquisition of surface Mo3e expression 
was a selective response of PMA-stimulated HUVEC (the surface expression of HU- 
VEC class I and class II histocompatibility antigens being unaltered) and was not due 
to an increase in nonspecific monoclonal antibody binding or a relative increase in 
the number of PMA-stimulated cells. The specificity of anti-Mo3e antibody for 
PMA-stimulated HUVEC (as opposed to small numbers of contaminating leuko- 
cytes) was documented by visual examination of monolayers stained by immu- 
nofluoresence and immunoperoxidase techniques which showed a homogeneous 
pattern of expression. Since HUVEC cultured in the absence of PMA, like unstimu- 
lated human monocytes (36), express little if any detectable surface Mo3e, we suggest 
that Mo3e may represent an activation marker of human endothelial cells as well as 
monocytes. In support of this hypothesis are the observations of Hancock and Todd 
(manuscript in preparation) that demonstrate preferential expression of Mo3e by 
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TABLE 4 
Plasma Membrane-Associated Components of Endothelial Cells Whose Expression 
Is Inducible by Soluble Stimuli” 
Surface component 
Stimuli inducing Distribution 
expression among nonendothelial cells’ Reference(s) 
H4/18 (~100, 120)’ 
ICAM-I (~97)’ 





IL- 1. TNF, LPSd 






IL- 1, LPS, TNFd 
None known 
Lymphoid cells; tissue macrophages; 
U-937 and HL-60 human cell 
lines 
Broad distribution including B 
lymphocytes, activated T 
lymphocytes, mononuclear 
phagocytes 
Broad distribution including 
lymphoid cells, neutrophils, and 
mononuclear phagocytes 






’ Selected list. 
b Among human cells. 
‘Molecular weight of polypeptides. 
d HUVEC in vitro. 
e Bovine pulmonary endothelial cells in vitro. 
macrophages within inflammatory foci (glomerulonephritis, allograft rejection, sar- 
coidosis, and appendicitis) of immunoperoxidase-stained frozen tissue sections. 
Among endothelial cells, capillary endothelium of normal ovary, lymph nodes, lung, 
and skin were weakly Mo3e positive but endothelial staining was more prominent in 
inflammatory specimens. Some Mo3e staining by “normal” macrophages and endo- 
thelial cells in these tissue specimens is consistent with our observation that there 
exists a sequestered pool of intracellular Mo3e detectable in fixed (permeabilized), 
unstimulated U-937 cells (73) and HUVEC (Table 2). 
While a “physiological” stimulus of HUVEC Mo3e expression has not as yet been 
identified (Table 3), we suspect that expression of surface Mo3e by PMA-stimulated 
HUVEC is not an in vitro artifact. We base this conclusion on the selective stimula- 
tory effects of PMA, 4PPDD, 4/3PDB, MEZ, and OAG, compounds which can mimic 
the effect of endogenous 1,2-diacylglycerol in activating protein kinase C (53, 54). 
The additive or synergistic effect of the calcium ionophore, ionomycin, and PMA 
suggests the additional contribution of intracellular calcium mobilization (59-63) to 
an activation process leading to surface Mo3e expression, These observations are 
therefore consistent with the notion that surface Mo3e expression by HUVEC is an 
effector response that depends upon protein kinase C activation and calcium mobili- 
zation stimulated by endogenous products of the phosphatidylinositol signal trans- 
duction pathway 1,2-diacylglycerol and inositol trisphosphate, respectively (53, 54). 
As demonstrated in other biological systems, these products are generated by phos- 
phatidylinositol hydrolysis stimulated by receptor-mediated ligand binding (53, 54). 
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The quest for a “natural” ligand that is stimulatory of Mo3e expression in HUVEC 
is still in progress. 
As shown in Table 4, Mo3e expression by PMA-stimulated HUVEC is one of sev- 
eral plasma membrane phenotypic changes associated with exposure of HUVEC to 
soluble activating stimuli. Included among these changes is the expression of ICAM- 
1 ( 18, 19), a 97-kDa adhesion-promoting molecule shared by human leukocytes (U- 
937, HL-60) (18) and endothelial cells cultured in the presence of PMA or certain 
natural cellular products of stimulated leukocytes (IL- 1, IFN--y, or TNF) (19). Its 
molecular weight and expression by lymphocytes clearly distinguish ICAM- from 
Mo3e (p75,50) (72). Also distinct from Mo3e is the H4/18 antigen (~100, 120) (37) 
which is a transient feature of HUVEC exposed to IL- 1 or TNF (37): its expression 
by HUVEC as measured by RIA reaches a peak at 3-6 hr of culture and then declines 
to undetectable baseline levels (37). Other surface components whose activity or den- 
sity is up-regulated by exposure to activating stimuli include endothelial cell procoag- 
ulant activity (stimulated in HUVEC by IL- 1, TNF, or LPS (22-25,27), class II histo- 
compatibility antigens (stimulated in HUVEC by PHA and IFN--r (14, 66)) and 
Fc receptors (stimulated in bovine pulmonary endothelial cells by leukocyte-derived 
lysates or infection with CMV or influenza virus ( 17)). 
The physiological significance of Mo3e expression by PMA-stimulated HUVEC is 
as yet unknown. We have previously reported that anti-Mo3e monoclonal antibody 
blocks the response of human monocytes to migration inhibitory factor (MIF), sug- 
gesting that Mo3e contributes to MIF responsiveness (74). Whether Mo3e itself repre- 
sents the surface receptor for MIF remains to be determined in direct ligand binding 
assays. What role Mo3e plays in the functional activity of endothelial cells is open to 
speculation but its capacity to promote the binding of MIF ligand by endothelial cells 
will be assessed. 
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